Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer

Tyrosine kinase inhibitors (TKIs) which target angiogenesis are promising treatments for patients with metastatic medullary and differentiated thyroid cancers. Sorafenib, sunitinib, and pazopanib are commercially available drugs which have been studied in these diseases. Vandetanib is the first drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Cabanillas, Maria E., Hu, Mimi I., Durand, Jean-Bernard, Busaidy, Naifa L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189619/
https://www.ncbi.nlm.nih.gov/pubmed/22007339
http://dx.doi.org/10.4061/2011/985780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3189619/
https://www.ncbi.nlm.nih.gov/pubmed/22007339
http://dx.doi.org/10.4061/2011/985780

Ejemplares similares